Email
Print
Burkholderia Infections Market - Forecast(2024 - 2030)
Burkholderia Infections Market Overview
Burkholderia Infections Market Size is estimated to reach $430
million by 2027 and is poised to grow at a CAGR of 7.2% over the forecast
period of 2022-2027. Burkholderia cepacia is the causative agent of Burkholderia
infections. It is a gram-negative bacillus found in the aquatic environment. It
is a low-virulent bacteria and is a frequent colonizer of fluids used in the
hospitals such as IV fluid, irrigation solutions and others. People with compromised immune systems or those with chronic lung disorders experience health issues as a result of B. cepacia. Patients with lung diseases
such as asthma, CFTR and COPD are at substantial risk of suffering from Burkholderia
infection. The increasing prevalence of lung diseases is anticipated to fuel the
growth of the Burkholderia infections industry. The exact cause of asthma and cystic
fibrosis is unknown, though the risk factors can be transferred from generation
to generation. According to Healthline, about 70,000 to 100,000 people around
the world suffered from cystic fibrosis in 2019. Also, more than sixty-five million
people around the world have moderate to severe CPOD. Such diseases increase
the risk of Burkholderia Infections and drive the growth of the Burkholderia
Infections Market over the forecast period 2022-2027.
Burkholderia Infections Market Report Coverage
The “Burkholderia Infections Market Forecast
(2022-2027)" by Industry ARC, covers an in-depth analysis of the following
segments in the Burkholderia Infections Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021, owing to the increasing awareness about this disease and rising demand for diagnostic tests, driving Burkholderia Infections Market size in this region.
- The Burkholderia Infections Market is predicted to increase owing to the growing prevalence of chronic lung diseases across the world fuelling the growth of the Burkholderia Infections Market. However, the lack of proper diagnostic techniques in Low and Middle-Income Countries (LMICs) may limit the Burkholderia Infections Industry growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Burkholderia Infections Market Report.
Burkholderia Infections Market Segment Analysis - by Drug
The Burkholderia Infections Market based on drugs can be further
segmented into Trimethoprim, Sulfamethoxazole, Trimethoprim &
Sulfamethoxazole, Meropenem, Mucolytics, Minocycline, Cefepime, Tigecycline, Bronchodilators,
Fluoroquinolones and Others. The Trimethoprim & Sulfamethoxazole segment held
a dominant market share in the year 2021. Trimethoprim & Sulfamethoxazole
is a commonly used drugs for the treatment of Burkholderia Infections. According
to the research paper published in the National Center for Biotechnology
Information (NCBI), a 17-year study in the United States shows a 94% success
rate for Trimethoprim & Sulfamethoxazole. Such a high success rate of Trimethoprim
& Sulfamethoxazole drugs for the treatment of Burkholderia Infections and
their growing demand drive the growth of the Burkholderia Infections Market
Share.
However, Cefepime is estimated to grow
with the fastest CAGR of 6.8% over the forecast period 2022-2027.
This is owing to the high antimicrobial activity of this drug. According to a
research article published in the Journal of Allergy and Clinical Immunology in
February 2021, the use of Cefepime is considered safe for the treatment of
cystic fibrosis in patients with multiple drug sensitivity. Such properties of
Cefepime increase their demand for treatment of Burkholderia Infections and
fuel growth of the Burkholderia Infections Market Share over the forecast
period 2022-2027.
Burkholderia Infections Market Segment Analysis - by Distribution Channel
The Burkholderia Infections Market based on the distribution channel can be further segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. The Hospital Pharmacy segment held a dominant market share in the year 2021. This is owing to growing cases of hospitalization for the treatment of chronic diseases. According to a research paper published in Springer Nature in July 2021, chronic diseases increase hospital admission by 23.2% in women and 28.5% in Male. Such growing hospital admission for the treatment of chronic diseases and long bed stay increases the risk of infection, which fuels the growth of various drugs such trimethoprim, sulfamethoxazole, trimethoprim & sulfamethoxazole, meropenem, mucolytics, minocycline, cefepime, tigecycline, Bronchodilators, Fluoroquinolones and others for the treatment of Burkholderia infection from the hospital pharmacy. The increasing demand for drugs in hospital pharmacy drive the growth of the Burkholderia Infections Market Share. However, Online Pharmacy is estimated to grow with the fastest CAGR of 6.0% over the forecast period 2022-2027. The high rate of internet penetration around the world and the availability of smartphones in the majority of populations surge the growth of online pharmacies. Owing to quick service, discounts on purchase and doorstep delivery of medicines online pharmacies touch the sky and propel the growth of the Burkholderia Infections Market Share over the forecast period 2022-2027.
Burkholderia Infections Market Segment Analysis - by Geography
North America held a dominant market share of 35% in the year 2021. This is the result of increasing cases of chronic diseases such as chronic lung diseases, cystic fibrosis and others, & growing risk of infection owing to a long hospital stays fueling the growth of the market. According to Cystic Fibrosis Organisation, about 40,000 children and adults living with cystic fibrosis in the United States in 2021. Such increasing prevalence of diseases related to Burkholderia infections drives the growth of the Burkholderia Infections Market Size. Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR of 9.0% over the forecast period 2022-2027. This is owing to the discovery of cases of melioidosis caused by Burkholderia pseudomallei in this region. The B.pseudomallei is mostly found in the tropical and subtropical areas which are majorly located in the Asia-pacific region. According to the research paper published in the Lancet in May 2022, South Asia has 44% of the world's burden of melioidosis. Bangladesh and Sri Lanka are two South Asian nations where melioidosis is reported to be endemic; a few cases have also been reported from Nepal and a few imported cases from Pakistan. Such a growing prevalence of melioidosis diseases and Burkholderia infection in this region fuels the growth of the Burkholderia Infections Market Size over the forecast period 2022-2027.
Burkholderia Infections Market Drivers
Growing Prevalence of Chronic Lung Diseases Drive Market Growth.
The increasing prevalence of chronic lung diseases increases the risk of Burkholderia infections. According to a research report published in the
British Medical Journal in July 2022, in 2019, 212.3 million prevalent cases of
COPD were reported globally, with COPD accounting for 3.3 million deaths and
74.4 million disability-adjusted life years (DALYs). In low- and middle-income
countries (LMIC), COPD fatalities in people under 70 years of age account for
about 90% of all mortality. The risk of respiratory tract infection rises along
with the severity of COPD. Both the colonization of the respiratory tract with
bacteria and the increased risk of infection with new strains of bacteria
inducing acute exacerbations are caused by the weakening of the
innate immune system. Such risk of Burkholderia infection in COPD and the growing
prevalence of COPD around the world, fuel the growth of the Burkholderia
Infections Industry over the forecast period 2022-2027.
Growing Investment for Development of Novel Drugs Drive Burkholderia Infections Market Growth.
In the case of Burkholderia Infections,
the chance of developing antibiotic resistance is extremely high. The outer
membrane penetration barrier serves as the Burkholderia species' first line of
defense against antimicrobials. A modified lipopolysaccharide found in the
majority of Burkholderia results in intrinsic polymyxin resistance. For
instance, researchers at Case Western Reserve University School of Medicine
received a US$ 3.34 million grant from the National Institutes of Health (NIH)
in February 2019 to investigate and develop a method for
sensitizing Burkholderia multivorans, a common pathogen found in patients
with lung diseases, to antibiotics. In August 2019, a grant of up to the US $20.7
million over two years was announced by the Biomedical Advanced Research and
Development Authority (BARDA) for VenatoRx Pharmaceuticals. Ventoux
Pharmaceuticals work with BARDA's Office of the Assistant Secretary for
Preparedness and Response (ASPR) and the Department of Defense's Defense Threat
Reduction Agency (DTRA) to test the effectiveness of the VNRX-5133 compound in
treating pathogens, specifically the melioidosis. Such growing investment
for new drug development to treat Burkholderia infection drive growth of the Burkholderia
Infections Industry over the forecast period 2022-2027.
Burkholderia Infections Market Challenges
Low Availability of Diagnostic Services is Hampering Market Growth
Accurate diagnosis is essential for effective therapy. Burkholderia infection can be diagnosed by removing Burkholderia pseudomallei from blood, urine, sputum, skin lesions, or abscesses, or by screening for a monoclonal antibody reaction to the bacteria. The availability of diagnosis centers affects the impact of Burkholderia infection, as undiagnosed infection cases have a substantial risk of spreading and severe cases of infection have a high mortality rate. According to the research report published in the Lancet in October 2021, the median availability of diagnostics was 19·1% in basic primary care facilities, 49·2% in advanced primary care facilities and 68·4% in hospitals. Availability also varied between countries, from 14·9% (Bangladesh) to 89·6% (Namibia). Such uneven diagnostic services in Low and Middle-Income Countries can partially restrain Burkholderia Infections Market expansion over the forecast period 2022-2027.
Burkholderia Infections Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Burkholderia
Infections Market. The top 10 companies in the Burkholderia Infections Market are:
- Novabiotics Ltd.
- Aridis Pharmaceuticals LLC
- NanoBio Corporation
- iQur Ltd.
- SUN Pharma
- Allergan plc
- Mylan N.V.
- Pfizer Inc.
- Purdue Pharma L.P.
- Janssen Pharmaceuticals Inc.
Recent Developments
- In June 2021, NovaBiotics Ltd., a privately held clinical-stage company announced that the Company’s proprietary intravenous (IV) cysteamine bitartrate (NM002) therapy candidate is included in a global Phase 3 clinical trial being conducted and funded as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia). NM002 is an immunomodulator-antimicrobial (antiviral and antibacterial) that provides significant benefits in the treatment of CAP.
- In March 2021, Aridis Pharmaceuticals, Inc announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. The agreement represents a continuation of Aridis' expansion into product discovery and development for viral pathogens.
- In January 2021, NANOBIOTIX a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, announced a new collaboration agreement secured by its owned subsidiary, Curadigm.
Relevant Reports
Report Code: HCR 0022
Report Code: CMR 246
Report Code: HCR 0876
For more Lifesciences and Healthcare Market reports, please click here